This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: CEPT inhibitors

August 2012 Br J Cardiol 2012;19:107–10

HDL particles may be key to risk

BJCardio Staff

Abstract

While the failure of the first cholesterylester transfer protein (CETP) inhibitor, torcetrapib, was blamed on its side effect of raising blood pressure, three more negative trials have also now cast doubt on the value of boosting HDL – AIM-HIGH with niacin, dal-OUTCOMES with dalcetrapib, and a genetic study published earlier this year in The Lancet, showing that people carrying gene variants coding for increased HDL levels did not have a reduced risk of heart disease. However, in a new analysis of the Multi-Ethnic Study of Atherosclerosis (MESA), published on July 11 in the Journal of the American College of Cardiology (http://dx.doi.org/10

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now